Prescient Therapeutics: Investor Briefing
Prescient Therapeutics: Investor Briefing with CEO and Managing Director, Steven Yatomi-Clarke CEO and Managing Director,...
Prescient Therapeutics: Investor Briefing with CEO and Managing Director, Steven Yatomi-Clarke CEO and Managing Director,...
Pitt Street Research Briefing on Prescient Therapeutics (ASX: PTX) Reach Markets interviewed Co-Founder and Senior...
Prescient Therapeutics: PTX-100 targeted cell therapy briefing Prescient Therapeutics CEO and MD Steven Yatomi-Clarke gave...
Prescient Therapeutics: Investor Briefing with CEO and Managing Director, Steven Yatomi-Clarke CEO and Managing Director,...
Prescient Therapeutics (ASX: PTX) had a solid FY23 that has set the stage for a...
Steven Yatomi-Clarke, CEO and MD of Prescient Therapeutics (ASX: PTX) recently presented at the TechKnow...
Hear Prescient Therapeutics (ASX: PTX) CEO and Managing Director Steven Yatomi-Clarke present at the TechKnow...
Prescient was pleased to present data on our cell therapies at the prestigious International Society...
Prescient Therapeutics: Cell Therapies presentations from ISCT Prescient Therapeutics held a special Cell Therapies briefing...
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke presented at the...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.